The IND submission is supported by clinical observations from Quoin's ongoing investigator-led pediatric PSS study. The initial subject has been treated with QRX003 for over 15 months and significant clinical improvements in skin, sleep patterns and overall quality of life have been achieved. QRX003 has been well tolerated, with no adverse events reported. The Phase 2 study is expected to recruit 6-8 pediatric and adult patients with PSS in both the US and Europe.